Evidence map›Paper›PMID 42223671›Full record

ArticleJournal of gastroenterology2026

Reelin level in serum-derived extracellular vesicles predicts regression of M2BPGi-defined liver fibrosis following hepatitis C virus eradication by direct-acting antiviral agents.

Takanori Suzuki, Kentaro Matsuura, Yutaka Hashimoto, Masako Okina, Mayumi Hojo, Hayato Kawamura, Kei Fujiwara, Katsuya Nagaoka, Takehisa Watanabe, Hiromi Kataoka and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Takanori SuzukiDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan.
Kentaro MatsuuraDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan. matsuura@med.nagoya-cu.ac.jp.
Yutaka HashimotoDepartment of Cell Biology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Masako OkinaDepartment of Core Laboratory, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Mayumi HojoDepartment of Virology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Hayato KawamuraDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan.
Kei FujiwaraDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan.
Katsuya NagaokaDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Takehisa WatanabeDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Hiromi KataokaDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho, Nagoya, Aichi, 467-8601, Japan.
Yasuhito TanakaDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Funding

Japan Agency for Medical Research and Development JP24fk0210113Japan Society for the Promotion of Science JP17K09435Japan Society for the Promotion of Science JP20K08314MEXTproject JPMXS0441500025
6 · The paper itself

Abstract

backgroundWe investigated serum-derived extracellular vesicle (EV)-associated proteins as predictors of liver fibrosis (LF) regression following sustained virological responses (SVR) in individuals with chronic hepatitis C (CHC) managed using direct-acting antiviral (DAA) therapy.

methodsWe retrospectively analyzed 107 CHC patients with pretreatment Mac-2 binding protein glycosylation isomer (M2BPGi) levels ≥ 2.0 cut-off index (COI). Two years after the end of treatment (EOT), participants were grouped according to the M2BPGi levels: regression group (M2BPGi < 1.76 COI) and non-regression group (M2BPGi ≥ 1.76 COI). Twelve patients were selected for the discovery cohort, where comprehensive protein profiling of serum-derived EVs was performed at 12-24 weeks post-EOT using quantitative mass spectrometry for label-free quantification. The remaining 95 patients formed the validation group, in which the identified EV proteins were further assessed via protein quantification using parallel reaction monitoring.

resultsReelin (RELN) and oncoprotein-induced transcript 3 (OIT3) protein had potential role as predictors of fibrosis regression in both groups. Multivariate analysis incorporating clinical parameters indicated that levels of RELN and OIT3 were associated with fibrosis regression (odds ratio [OR] = 1.510; P = 0.022 for log

conclusionsSerum-derived EV levels of RELN show promise as predictor of LF regression in CHC patients following SVR.

Indexed as

Antigens, NeoplasmAntiviral AgentsCell Adhesion Molecules, NeuronalExtracellular Matrix ProteinsExtracellular VesiclesHepatitis C, ChronicLiver CirrhosisMembrane GlycoproteinsNerve Tissue ProteinsSerine EndopeptidasesAdultAgedBiomarkersFemaleHumansMaleAntigens, NeoplasmAntiviral AgentsBiomarkersCell Adhesion Molecules, NeuronalExtracellular Matrix ProteinsMembrane GlycoproteinsNerve Tissue ProteinsReelin ProteinRELN protein, humanSerine EndopeptidasesTAA90K protein, humanEVsExtracellular vesiclesLiver fibrosis regressionMac-2-binding protein glycosylation isomer (M2BPGi)Oncoprotein-induced transcript 3 proteinReelin

Identifiers

PMID42223671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.